Mylan Launches Generic Epivir-HBV Tablets

(RTTNews) - Mylan Inc (MYL) on Thursday announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's Epivir-HBV. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation.

Lamivudine Tablets, 100 mg, had U.S. sales of about $18.1 million for the 12 months ending September 2014, according to IMS Health.